The evidence clearly establishes PHI-1 as a key driver of tumor progression, therapy resistance, and immune evasion, highlighting its clinical versatility as a diagnostic, prognostic, and predictive biomarker. This evidence concerns the gene PPP1R14B and neoplasm.